Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey

Upon its January approval by the FDA, Roche’s Vabysmo registered an impressive trio of firsts.

It is the first injectable drug in the United States approved simultaneously to treat both wet-age macular degeneration (AMD) and diabetic macular edema (DME). It’s the first bispecific antibody for the eye. And—most importantly—it is the first injectable that can work for up to four months.